Several novel CDK inhibitors were detected in addition to a detailed knowledge of CDK roles in various breast cancer subtypes, including the results of using CDK4/CDK6 inhibitors in HR-positive/HER2-negative metastatic and advanced breast cancers, with the emergence of resistance and the side effects of the present inhibitors [113]. The gene discussed is ERBB2; the disease is breast carcinoma.